MED12 and neoplasm: In this model, the growth of tumors derived from H3122/MED12 KO cells was significantly suppressed in the trametinib-treated group compared to both the vehicle and ceritinib-treated groups, suggesting that trametinib is effective in inhibiting tumor progression despite the presence of MED12 functional loss (Fig. 4D, E).